Carrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable CNLC Stage IIa/IIb (BCLC Stage B) Hepatocellular Carcinoma: Randomized, Open, Parallel Control, Phase 2/3 Sequential Research
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 07 Aug 2024 Planned primary completion date changed from 1 Mar 2024 to 31 Jul 2025.
- 07 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Primary Results (n=119; of phase II stage) assessing the efficacy and safety of camrelizumab plus apatinib (C+A) as a perioperative regimen in resectable HCC at intermediate-high risk of recurrence presented at the 59th Annual Meeting of the American Society of Clinical Oncology